oppn parties Sub-Standard Drugs: India Must Take Strict Action

News Snippets

  • Government to introduce PF for self-emplyed and gig workers
  • Crush at Puri Rathyatra leaves 2 dead and 78 injured
  • NEET-UG, marred in controversy due to pape4r leak, saw a huge increase in top scores as two scored 715/720 and 11.2 lkah candidates cleared the exam
  • India's first hydrogen-powered train will be flagged off by PM Modi from Jind in Haryana
  • Delhi HC asks the government to monitor Sona Wnagchuk's health regularly
  • TMC Rajya Sabha MP Koel Mallick resigns from her seat, leaves TMC. Mamata asks all those wishing to leave the party to do so before July 21
  • Calcutta HC says land deed is not a proof of citizenship. Refuses to provide protection to a man facing deportation on basis of land deed
  • Supreme Court tells the government to teach the third language in the 3-language formula in Class 6 and not Class 9
  • Government to take steps to boost liquidity for small businesses
  • RBI says that banks cannot sell seized assets back to the defaulters
  • Centre decides to take equity stakes in semiconductor startups
  • Markets remain flat on Thursday: Sensex closes just 1 point ahead and Nifty ended 5 point lower
  • BCCI:Selectors have possibly decided that Rohit Sharma will not be selected for ODIs after the Lord's game on Sunday
  • Japan Open badminton: P V Sindhu stuns world no. 5 Han Yue of China 21-16, 21-14 to enter the quarterfinals
  • 2nd ODI versus England: Indian batting fails miserably except Gill, Kohli and Iyer to score just 233 all out. England win by 4 wickets
Supreme Court clarifies that it has not issued a blanket ban on use of bulldozers, and they can be used after compliance with procedure laid down in civil laws
oppn parties
Sub-Standard Drugs: India Must Take Strict Action

By Sunil Garodia
First publised on 2022-12-31 07:54:11

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator. Author of Cyber Scams in India, Digital Arrest, The Money Trap and The Human Hack

The position of India as the pharmacy of the world (for supplying generic medicines at low cost) is in danger after two successive incidents of supply of allegedly sub-standard and/or spurious products. Close on the heels of ruckus raised by the death of more than 66 children in Gambia (which was allegedly flagged by WHO without proper preliminary inquiry) by drinking paediatric cough syrups made in India by Haryana-based Maiden Pharmaceuticals which allegedly deed not meet the prescribed standards (an inquiry by the Indian government exonerated the manufacturer of any wrongdoing) comes the allegation from Uzbekistan that many children have died there after consuming cough syrups made and supplied by Noida-based Marion Biotech Private Limited. Drug regulators in India have asked the firm to stop production pending an investigation.

Even though nothing has been heard further about the Gambia case (although one is sure that the Central government is taking it up in all forums), this new case complicates matter further. In addition, data from Central Drugs Standard Control Organization (CDSCO) shows that out of 1487 samples picked up by regulatory agencies from drug manufacturers' facilities across India, 83 or 6% were found to be sub-standard. Greed, and the desire to make extra profits, leads some dirty fish among drug manufacturers to use sub-standard material or play around with accepted formulas to endanger lives. This cannot be allowed. Manufacturers have to adhere to good manufacturing practises (GMP) and ensure that no sub-standard product leaves their manufacturing facilities.

The Indian Pharmaceuticals Alliance and the Central and state governments have a huge role in ensuring this. There should be mandatory random checks of export consignments (in addition to periodic checks at manufacturing facilities). Drug manufacturers and the government have to all to ensure that India pharmaceuticals products meet accepted world standards and there is no deviation to maintain India's place as the prominent drug supplier in the world. Drug manufacturers found indulging in cutting corners should be punished as per law and their licences should be cancelled even if one wilful deviation is detected and the promoters should be blacklisted and denied licence to manufacture pharmaceutical drugs in future.